# Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial

> **NCT04106024** · PHASE2 · UNKNOWN · sponsor: **Cttq** · enrollment: 60 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04106024
- **Lead sponsor:** Cttq
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-23
- **Primary completion:** 2019-10-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106024, "Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04106024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*